Regulating GSK3β activity is a promising candidate for alleviating cognitive symptoms associated with psychiatric and neurodegenerative diseases, albeit how current pharmacological agents mediate their beneficial properties remains unclear. This evidence concerns the gene GSK3B and neurodegenerative disease.